Selectis Health (GBCS) Cash & Equivalents (2010 - 2026)

Selectis Health has reported Cash & Equivalents for 16 years, with the latest figure at $1.0 million in Q4 2025.

• Quarterly Cash & Equivalents rose 48.7% year-over-year to $1.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.0 million (up 48.7% YoY) and the FY2025 annual result came in at $1.0 million, up 48.7% from the prior year.
• Cash & Equivalents climbed to $1.0 million in Q4 2025 per GBCS's latest filing, from $806886.0 in the prior quarter.
• Over five years, Cash & Equivalents peaked at $3.9 million in Q4 2021 and troughed at $410866.0 in Q1 2021.
• A 5-year average of $1.5 million and a median of $969720.0 in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2021 and 2022: Cash & Equivalents surged 723.66% in 2021, then plunged 76.99% in 2022.
• Over 5 years, Cash & Equivalents stood at $3.9 million in 2021, then sank by 38.66% to $2.4 million in 2022, then sank by 38.57% to $1.5 million in 2023, then tumbled by 54.17% to $680332.0 in 2024, then surged by 48.7% to $1.0 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $1.0 million, $806886.0, and $771940.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.